23 We have also tested OG1950 and KSI-301 in vitro alongside other anti-VEGF biologics to test their respective abilities to inhibit VEGF from binding to VEGF receptors. As shown in the figure and table below, while KSI-301 and OG1950 have similar IC50 (the concentration at which binding is reduced by half) compared to EYLEA, KSI-301 consistently demonstrates a higher maximal inhibition than EYLEA or Lucentis. Of note, KSI-301 improved maximal inhibition more than OG1950, suggesting that the special nature of our antibody biopolymer conjugate synergistically improves the bioactivity of the antibody intermediate acting alone. Figure: Inhibition of VEGF binding to VEGF receptors by anti-VEGF agents. Molecule IC50 (nM) Maximal inhibition (%) KSI-301 ........................................................................................................................ 3.72±0.74 93.89±1.41 OG1950 ........................................................................................................................ 3.97±1.19 83.72±3.13 Ranibizumab (Lucentis) ............................................................................................... 8.60±1.29 70.67±2.36 Aflibercept (EYLEA)................................................................................................... 4.50±0.14 74.96±1.84 Bevacizumab (Avastin)................................................................................................ 10.29±0.70 73.08±4.20 Table: Average IC50 and maximal inhibition of anti-VEGF agents. IC50 values measured in nanomoles (nM) and calculated from concentration of anti-VEGF agents. All values shown as average with standard deviation.